Introduction
Mantle cell lymphoma (MCL) is a distinct pathologic entity characterized by malignant B lymphocytes derived from the mantle zone of the germinal center. 1, 2 This is a clonal disease of intermediate-sized, IgM+, IgD+ B cells with unique morphologic, immunophenotypic and genetic features. This subset of non-Hodgkin's lymphoma (NHL) previously has been termed 'centrocytic lymphoma' or 'intermediate cell lymphoma.' A recent evaluation by the International Lymphoma Study Group indicated that this entity accounts for approximately 6% of NHL cases worldwide. 3 The clinical course is characterized by presentation in middle age, often with advanced stage including generalized lymphadenopathy and splenomegaly. 4, 5 Although circulating malignant cells are occasionally detected in the peripheral blood, frank leukemia is unusual. 6, 7 The prognosis for patients with MCL is poor, and in most cases there is only a limited response to conventional chemotherapy. 2, 3 MCL cells can be distinguished from those of other NHLs and lymphocytic leukemias by the expression of surface Ig (IgM and IgD), CD5 and CD19, and by the lack of CD10 and CD23. 8 A defining aspect of this disease is overexpression in the tumor cells of cyclin D1, which in most cases occurs due to an (11;14)(q13;q32) translocation involving the PRAD1 proto-oncogene at the bcl-1 locus. In normal cells, cyclin D1 regulates cell cycle progression through the main commitment checkpoint between G 1 and S phase. 9 In as many as 30-50% of MCL cases, the t(11;14) translocation is not detected by conventional cytogenetic analyses or by Southern blotting. In such cases, cyclin D1 overexpression can be confirmed by Western blot or immunohistochemical analysis. 10 Despite considerable progress in our ability to identify and categorize this tumor, little is known about its specific growth characteristics and immunologic features. Like most B cells, MCL cells express CD40, a tumor necrosis factor receptor family member that regulates B cell proliferation, survival and apoptosis. 11 The physiologic ligand for CD40 is CD154 (CD40 ligand), which is expressed transiently by activated CD4 + T lymphocytes. 12, 13 Although signaling via CD40 most often confers positive survival, proliferation and differentiation signals to normal and malignant B cells, [14] [15] [16] recent studies suggest that the outcome of CD40 signaling depends on the particular stage of B cell differentiation or tumor type. For example, in Epstein-Barr virus (EBV)-transformed lymphoblastoid B cells, CD40-mediated signals can induce growth inhibition, 17 and even cell death. 18 IL-4 is a T cell-derived cytokine which in general confers differentiation and survival signals of B cells in the context of CD40 ligation, 19, 20 but has been reported in some instances to have a negative effect on lymphoma cell proliferation in vitro. 21, 22 Based on observations that naive, IgM, IgD+ B cells are exquisitely sensitive to stimulation via CD40 and IL-4, 23 we hypothesized that these T cell-derived factors would have a positive effect on growth and proliferation of MCL B cells. To examine this question, we evaluated cellular proliferation, expression of nuclear regulatory proteins, and cell cycle in MCL cells exposed to IL-4 and CD40 ligation. The studies demonstrate that MCL B cells are highly responsive to IL-4 and CD40 ligation, which act in concert to stimulate cell proliferation and S-phase entry.
Materials and methods

Patient samples
Malignant B cells from the peripheral blood (two cases), and in other instances from pathologic lymph node specimens (four cases), were obtained through The Department of Pathology at The New York Hospital-Cornell Medical Center (Table 1) . Mononuclear cells were isolated by density centrifugation, phenotyped, and aliquoted prior to cryopreservation. In each case, the diagnosis of MCL was established by morphology and the clinical context, and was confirmed by detection of a bcl-1 rearrangement by Southern blot analysis, and/or by detection of cyclin D1 protein. For experiments with cells from the first and sixth cases, in which the MCL occurred in leukemic phase, B cells were purified from peripheral blood by standard techniques immediately prior to use. For the remaining studies, we used thawed cells that had been cryopreserved after isolation of the mononuclear cells from the tissue specimens. 
Culture conditions and reagents
MCL cells were placed in culture using RPMI media supplemented with penicillin, streptomycin, L-glutamine and 20% fetal calf serum, and incubated at 37°C in the presence of 5% CO 2 . After preliminary studies in which we evaluated the optimal concentration and conditions for cell culture, MCL cells were placed in culture at initial concentrations of 1.5 × 10 6 cells/ml. As indicated, the cells were exposed to IL-2 (40 ng/ml; Hemagen Diagnostics, Waltham, MA, USA), IL-4 (10 ng/ml; Genzyme Diagnostics, Cambridge, MA, USA), IL-10 (10 ng/ml; Genzyme), anti-CD40 monoclonal antibody (mAb), (1 g/ml, murine IgG 1 ; Genzyme), anti-CD23 mAb (1 g/ml, murine IgG 1 , EBVCS2; ATCC, Rockville, MD, USA), anti-IL4 receptor mAb (5 g/ml, murine IgG 1 ; Genzyme), and anti-CD154 mAb (anti-CD40L, 5 g/ml, murine IgG 1 , TRAP clone; PharMingen, San Diego, CA, USA). For coculture experiments, we used cells of the D1.1 mutant Jurkat cell line, which constitutively express CD154 (CD40L, gift of Dr Seth Lederman, Columbia University, New York, NY). 24 The D1.1 cells were irradiated (3 Gy) prior to coculture with target B cells.
AlamarBlue cell proliferation assay
The AlamarBlue fluorometric/colorimetric growth indicator (Biosource International, Camarillo, CA, USA) was used to measure cell proliferation. 25, 26 For each experiment, 3 × 10 4 cells were placed in triplicate cultures in 96-well roundbottom microplates. After 72 h, AlamarBlue was added to each well (10% by volume) and the proliferating cell populations evaluated by spectroscopy (excitation 530 nm, emission 590 nm) using a CytoFluor 2350 fluorescent plate reader (Millipore Corporation, Bedford, MA, USA) at the time points indicated. For each circumstance, the relative number of proliferating cells was determined according to the formula:
where 'E' is the mean fluorescence scanning result for the experimental triplicate, 'B' is the same for triplicate wells with media only (no cells), and 'M' is the result for the triplicate wells of the same cells, in the same experiment, with media only.
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Immunophenotyping and fixation
After 48 h in culture with or without irradiated effector T cells and cytokines, MCL cells were harvested and immunophenotyped using fluorescein isothiocyanate (FITC)-conjugated antihuman CD3 antibody (OKT3), such that in subsequent flow cytometric analyses we could exclude any remaining T cells by negative gating. For detection of Ki-67, PCNA and cyclin D1, the labelled cells were washed with cold PBS, fixed with 0.1% paraformaldehyde at 4°C for 4 h, washed again with cold PBS, and resuspended overnight in 70% EtOH in glycerol. Next, the cells were washed twice in PBS containing 1% BSA and 0.05% Tween 20, exposed to anti-Ki-67 mAb (Pharmingen), anti-PCNA mAb (Sigma, St Louis, MO, USA), anti-cyclin D1 (Pharmingen), or an isotype-matched murine control antibody (clone G124-326; Pharmingen), washed twice with PBS, and labelled with Cy5-conjugated polyclonal anti-mouse IgG (Caltag, Burlingame, CA, USA). At the end of each staining procedure, the cells were washed in cold PBS and resuspended in propidium iodide (PI) at 50 g/ml in PBS, with RNase at 100 U/ml prior to analysis by FACS.
Flow cytometry
Flow cytometry was performed using a Becton Dickinson FACSCalibur with an argon ion laser emitting at 488 nm for excitation of FITC and PI, and a diode laser emitting at 631 nm for excitation of Cy5. FITC, PI and Cy5 were detected through 535/30,575/20 and 670/20 nm narrow bandpass filters, respectively. Data were acquired using CellQuest acquisition software (Becton Dickinson, San Jose, CA, USA) and analyzed using WinMDI ver. 2.5 (Dr Joseph Trotter, The Scripps Institute) and WinList ver. 3.0 (Verity Software House, Topsham, ME, USA). Linear PMT response over the appropriate fluorescence range was confirmed using standardized fluorescent microbeads (Flow Cytometry Standards Corporation, San Juan, PR).
Results
MCL cells proliferate in response to CD40 ligation and IL-4 exposure in vitro
Cases of MCL were identified by histologic and immunophenotypic analysis in The Department of Pathology at The New
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York Hospital, and the diagnosis of MCL confirmed by detection of a bcl-1 rearrangement and/or cyclin D1 overexpression ( Table 1 ). The cells were placed in culture with media alone, with IL-4, with an agonist anti-CD40 mAb, or with the combination of IL-4 and anti-CD40 mAb, and after 3 days the proliferating cell populations were measured using the AlamarBlue fluorometric cell growth indicator (Figure 1a) . In this representative experiment with MCL cells of one case, the proliferating cells were most numerous after exposure to IL-4, or to the combination of IL-4 and anti-CD40 mAb. Although CD40 ligation alone did not induce MCL cell proliferation, there was a positive effect when this stimulus was applied together with IL-4. Neither IL-10, nor a control, isotype-matched antibody to CD23, had any effect on MCL cell proliferation in vitro. Consistent with these results, in each of four cases analyzed for this effect, the number of viable MCL cells was greatest after culture with IL-4 or with the combination of IL-4 and anti-CD40 mAb, as compared to the same cells exposed only to media or anti-CD40 mAb (Figure 1b ).
MCL cells enter S phase after CD40 ligation and IL-4 exposure
The Ki-67 antigen is a sensitive marker for mammalian cells in S phase. 27 To evaluate the responsiveness of MCL cells to CD40 ligation and IL-4 exposure, we performed multiparametric flow cytometry analyses for expression of Ki-67 simultaneously with PI-based cell cycle studies. For these experiments, we employed the CD154 + Jurkat T cell clone D1.1 as an effector of CD40 ligation in MCL cells. 12 We chose this method to achieve CD40 ligation because cell-bound CD154 is a more potent stimulus to CD40 than is soluble antibody, and we had the capacity to identify specific changes in MCL B cells by immunolabelling prior to FACS analysis. As indicated in Figure 2 , which includes representative data from one of four cases analyzed in this manner, MCL cells were placed in culture with media alone, with IL-4, with irradiated, effector T cells that express CD154 (CD154T xr ), or with the combination of IL-4 and CD154T xr . In addition, MCL cells were exposed to these stimuli in the presence of blocking antibody to CD154 or to the IL-4 receptor (IL-4R). After 48 h of culture, MCL B cells were examined for cell cycle and activation antigen expression. As shown in the upper panel, there was a low level of Ki-67 detected in MCL cells exposed only to media (mean Cy-channel fluorescence, MCF, 71). Ki-67 expression increased slightly after exposure to IL-4 alone, but rose dramatically after exposure to CD154 (MCF 273). Addition of both IL-4 and CD154 resulted in augmented Ki-67 expression (MCF 281) in MCL cells, which was inhibited by culture with antibody to IL-4R, or to CD154 (MCF 251 and 196, respectively). An alternative marker for S-phase entry is the proliferating cell nuclear antigen (PCNA), or 'Cyclin' nuclear protein. PCNA serves as an auxiliary protein of DNA-polymerase delta (DNA polymerase III). 28, 29 It is expressed in cells as they exit G 1 and traverse S phase, and can be detected in tumor cell samples using monoclonal antibody. 30 The data in the middle panel of Figure 2 demonstrate nuclear staining for PCNA, and reveal low expression of PCNA in unstimulated MCL cells (MCF 110). Similar to the results for Ki-67, PCNA increased dramatically after coculture of the MCL B cells with CD154-expressing T cells (MCF 500), and was induced slightly after exposure to IL-4 alone. Here again, the combination of IL-4 and CD40 ligation yielded the strongest effect (MCF 537), which was reduced by either antibody to IL-4R or to CD154.
PI binds directly to DNA and, in permeabilized cells, thereby affords measurement of DNA content and cell cycle by FACS. We performed cell cycle analyses, using cells of four distinct cases, in experiments similar to that shown in Figure 2 . In each experiment, unstimulated MCL cells were predominantly in the G 0 /G 1 phase of the cell cycle. Figure 3 shows the composite results for S-phase entry in the four cases examined. As indicated, the average percent of MCL cells in S phase after culture with media alone was 8%. The addition of IL-4 alone did not significantly impact the cell cycle profile (6%), but marked S-phase entry was observed in MCL cells stimulated by CD154 (22%). This effect was enhanced by the addition of IL-4 in each case analyzed (mean S-phase fraction 34%). In MCL cells exposed to the combination of CD40 ligation and IL-4, S-phase entry was significantly blocked by antibody to CD154 (17%) and was minimally affected by antibody to the IL-4 receptor (27%).
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Figure 3
S-phase entry of stimulated MCL cells. MCL cells from four cases were stimulated and evaluated for DNA content using PI as in Figure 2 . In each experiment, the S-phase fraction was determined according to a standardized gate, based on DNA content between that of the diploid and tetrapoloid peaks. Error bars represent the s.e.m.
Analysis of cyclin D1 expression in the stimulated MCL B cells
Our present study raised the question of whether cyclin D1 expression undergoes cell cycle-related changes in CD40 and cytokine-stimulated MCL cells. In nonmalignant lymphocytes, cyclin D1 is expressed in cells in G 0 /G 1 and is normally suppressed as the cells traverse G 1 and enter S phase. 31 The data in Figure 4 demonstrate cyclin D1 expression upon forced Sphase entry in MCL cells stimulated by CD154 and IL-4. These data are representative of that from two cases analyzed in this manner. As shown, cyclin D1 protein was evident in unstimulated MCL cells, which were predominantly in G 0 /G 1 . After exposure to IL-4 there was a minimal shift toward the right in 
Discussion
Recent advances in our understanding of B cell development have facilitated our capacity to identify molecular features of the lymphocytic malignancies as they relate to specific compartments of the germinal center. Naive IgD+/IgM+ B cells, which constitute an important component of the B cells in the mantle zone of the germinal center, proliferate in response to IL-4 and CD40 ligation. 23 In the studies presented here, we demonstrate that ligation of CD40 in MCL cells results in Sphase entry. This process is characterized by augmented expression of the nuclear proliferation antigens Ki-67 and PCNA, and is enhanced by the addition of IL-4. In addition, the date indicate that MCL cells stimulated to enter S phase by CD154 and IL-4 express cyclin D1 throughout the cell cycle.
Although CD40 ligation generally confers proliferative and survival signals to normal B cells, the effects of CD40 signaling in malignant B cells are not straightforward. In one of the first descriptions of the consequences of CD40 ligation in malignant B cells, Ledbetter and coworkers reported that some, but not all, human B cell lymphoma cells could be induced to proliferate in vitro by exposure to antibody to CD40 (anti-Bp50, G28-5). 16 Heath used polyclonal rabbit anti-murine CD40 serum to stimulate murine splenic B cells, and observed a clear proliferative effect of this serum when applied to dense splenic B cells in the presence of IL-4. In the same set of experiments, addition of the serum to murine A.20 B lymphoma cells inhibited proliferation. 32 Together, these data indicate that the same CD40-mediated signal can yield diverse outcomes, depending on the B cell target. Our group has reported that in Burkitt's lymphoma, a tumor of germinal center B cells, CD40 ligation results in Fas induction such that the cells are primed for death by their interaction with CD154-expressing T cells. 33, 34 On the other hand, ligation of CD40 in human lymphoblastoid B cells can directly suppress B cell growth and inhibit S-phase entry. 17 In chronic lymphocytic leukemia, CD40 ligation can inhibit apoptosis and prolong cell survival in vitro. 35 Thus, the B cell tumors, as they represent outgrowths of B cells in different stages of ontogeny and activation, demonstrate distinct responses to CD40 ligation.
The positive impact of IL-4 in MCL cell proliferation is distinct from the suppressive effects reported for this cytokine in certain other human and murine B cell malignancies. For example, Defrance and coworkers reported that IL-2-dependent growth of cells from nine out of 10 human NHL cases analyzed, mainly of the follicle center cell type, was inhibited by the addition of IL-4 to the culture medium. 21 In a model for human B cell tumors using a xenografted Epstein-Barr viruspositive Burkitt's line in SCID mice, IL-4 had a suppressive effect on lymphoma growth. 22 Similarly, Bishop reported that in murine lymphoma CHB3 cells, which resemble human MCL cells in that they coexpress sIgM and sIgD, the cells respond negatively to IL-4 exposure. 37 Based on these reports and others, some investigators have proposed that IL-4 might be useful in the treatment of certain hematologic malignancies including B cell tumors. 38 Alternatively, IL-4 has been reported to stimulate proliferation of certain B cell tumors such as CLL, particularly in the context of concomitant CD40 ligation. 19, 39 Dancescu reported that IL-4 exposure induced Bcl-2 expression in CLL B cells, and inhibited apoptosis of those cells in vitro. 40 Although it is well established that MCL cells overexpress cyclin D1, it is not known how cyclin D1 relates to transformation, lymphomagenesis and tumor growth. Our analyses confirmed constitutive cyclin D1 expression in the MCL cells which, in the cases analyzed, remained inappropriately high as the cells traversed the cell cycle after stimulation. These data support that cyclin D1 is abnormally regulated in MCL B cells induced to enter S phase. Further investigations are warranted to explore the functional significance of unscheduled expression of cyclin D1 in MCL cells.
These data clearly indicate that MCL cells are activated and enter S phase in response to CD40 ligation by T cells in coculture. This process is augmented in the presence of IL-4 and inhibited by antibody to CD154. We would suggest that CD40-mediated alteration of cell cycle could be exploited to render some chemotherapies more effective, as this manipu-lation would increase the sensitivity to agents which affect only proliferating cells. Alternatively, the proliferative effect upon CD40 ligation might outweigh any benefit of enhanced sensitivity to some chemotherapy agents. These considerations require further studies to evaluate the response of stimulated MCL cells to specific chemotherapy agents, which may vary among clinical cases. Finally, these data implicate CD4 + T cells, which are the usual source of CD154 and IL-4 in vivo, in regulation of MCL cell cycle and activation state. Based on these observations, we speculate that some of the clinical effects of adenosine analogues, which result in prolonged depletion of CD4 + T cells, 41 may occur indirectly, through depletion of the host's nonmalignant T cells and consequent loss of T cell-derived B cell stimulatory factors such as CD154 and IL-4. 
